市場調査レポート

商品コード

1663811

メタボロミクス市場規模、シェア、成長分析、製品別、バイオインフォマティクスツールとサービス別、用途別、適応症別、エンドユーザー別、企業タイプ別、地域別-2025-2032年産業予測

Metabolomics Market Size, Share, and Growth Analysis, By Product, By Bioinformatics Tools and Services, By Application, By Indication, By End User, By Company Type, By Region - Industry Forecast 2025-2032

出版日: 2025年02月22日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

メタボロミクス市場規模は2023年に41億米ドルと評価され、2024年の46億7,000万米ドルから2032年には131億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは13.8％で成長する見通しです。

メタボロミクス市場は、精密医療における採用の増加や慢性疾患の診断法の進化により、大きな成長が見込まれています。主な促進要因としては、製薬セクターにおける研究開発投資の増加、分析技術、特に核磁気共鳴分光法や質量分析法の進歩が挙げられ、これによりさまざまな生体サンプル中の代謝物の包括的な分析が可能になります。この高度化により、糖尿病、心臓病、がんなどの疾患に関連する代謝異常の理解が深まる。個人の代謝シグネチャーを明らかにすることで、メタボロミクスはオーダーメイド医療を促進し、より良い疾患予測と個別化された管理戦略を可能にします。研究によって新しい代謝物や相互作用が発見されるにつれ、ターゲットおよびアンターゲットのメタボロミクスサービスに対する需要は増加し、ヘルスケアイノベーションにおけるメタボロミクスの重要性は確固たるものとなるでしょう。

市場概要
メタボロミクス機器
分離ツール
- ガスクロマトグラフィー
- 高速液体クロマトグラフィー
- 超高速液体クロマトグラフィー
- キャピラリー電気泳動
検出ツール
- 核磁気共鳴（NMR）分光法
- 質量分析（MS）
- 表面ベースの質量分析

メタボロミクス市場規模：バイオインフォマティクスツールとサービス別 & CAGR（2025-2032）

市場概要
バイオインフォマティクスサービス
バイオインフォマティクスツールとデータベース

メタボロミクス市場規模：用途別& CAGR（2025-2032）

市場概要
バイオマーカーの発見
創薬
毒性試験
ニュートリゲノミクス
機能ゲノミクス
個別化医療
その他の用途

メタボロミクス市場規模：適応症別& CAGR（2025-2032）

市場概要
がん
心血管疾患
神経疾患
代謝障害
先天性代謝異常
その他の適応症

メタボロミクス市場規模：エンドユーザー別& CAGR（2025-2032）

市場概要
学術研究機関
製薬・バイオテクノロジー企業
契約調査機関
その他のエンドユーザー

メタボロミクス市場規模：企業タイプ別& CAGR（2025-2032）

市場概要
ティア1製薬会社
ティア2製薬会社
ティア3製薬会社

メタボロミクス市場規模：地域別& CAGR（2025-2032）

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Agilent Technologies, Inc.（US）
Thermo Fisher Scientific, Inc.（US）
Waters Corporation（US）
Bruker Corporation（US）
Shimadzu Corporation（Japan）
Danaher Corporation（SCIEX）（US）
PerkinElmer, Inc.（US）
Merck KGaA（Germany）
Bio-Rad Laboratories, Inc.（US）
Metabolon, Inc.（US）
LECO Corporation（US）
Human Metabolome Technologies, Inc.（Japan）
GL Sciences, Inc.（Japan）
Bioocrates Life Sciences AG（Austria）
BASF SE（Germany）
MS-OMICS（Various locations）
Afekta Technologies Ltd.（Finland）
DNA Xperts Private Limited.（India）
Metabolomic Technologies Inc.（Canada）
Kore Technology Ltd.（UK）

結論と提言

Product Code: SQMIG35H2164

Metabolomics Market size was valued at USD 4.1 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 13.12 billion by 2032, growing at a CAGR of 13.8% during the forecast period (2025-2032).

The metabolomics market is poised for significant growth due to its increasing adoption in precision medicine and evolving diagnostics for chronic conditions. Key drivers include rising R&D investments in the pharmaceutical sector and advancements in analytical techniques, particularly nuclear magnetic resonance spectroscopy and mass spectrometry, which enable the comprehensive analysis of metabolites in various biological samples. This sophistication enhances our understanding of metabolic dysregulation associated with diseases like diabetes, heart disease, and cancer. By revealing individual metabolic signatures, metabolomics facilitates tailored medical care, enabling better disease prediction and personalized management strategies. As research uncovers novel metabolites and interactions, the demand for targeted and untargeted metabolomics services is set to rise, solidifying its importance in healthcare innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Metabolomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Metabolomics Market Segments Analysis

Global Metabolomics Market is segmented by Product, Bioinformatics Tools and Services, Application, Indication, End User, Company Type and region. Based on Product, the market is segmented into Metabolomics Instruments, Separation Tools and Detection Tools. Based on Bioinformatics Tools and Services, the market is segmented into Bioinformatics Services and Bioinformatics Tools and Databases. Based on Application, the market is segmented into Biomarker discovery, Drug discovery, Toxicology testing, Nutrigenomics, Functional Genomics, Personalized medicine and Other Applications. Based on Indication, the market is segmented into Cancer, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders, Inborn Errors of Metabolism and Other Indications. Based on End User, the market is segmented into Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End Users. Based on Company Type, the market is segmented into Tier 1 Pharmaceutical Companies, Tier 2 Pharmaceutical Companies and Tier 3 Pharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Metabolomics Market

Metabolite profiling within biological matrices plays a crucial role in discovering biomarkers and advancing personalized medicine. Through metabolomics studies, researchers can identify various biomarkers associated with intricate clinical phenotypes across multiple biological systems. This process is instrumental in the development of tailored medical treatments, focusing on optimizing therapeutic effectiveness while addressing potential toxicity issues. By employing metabolomics, healthcare providers can enhance patient outcomes by ensuring that medical interventions are more aligned with individual biological responses, ultimately paving the way for a more personalized approach to healthcare.

Restraints in the Metabolomics Market

The Metabolomics market faces significant restraints due to the rapid increase in high-volume and heterogeneous data generation, which exacerbates the existing complexity surrounding data management. As life science research produces increasingly intricate and multifaceted data, accurately evaluating high-dimensional information becomes a daunting challenge. This heightened complexity is anticipated to hinder the growth of the Metabolomics market, as researchers and organizations struggle to effectively analyze and interpret the data generated. Consequently, the difficulty in managing such complicated datasets may limit advancements and adoption within the sector, ultimately restraining its potential expansion and innovation.

Market Trends of the Metabolomics Market

The Metabolomics market is witnessing a significant upward trend driven by the expanding applications of biomarkers derived from bioinformatics analyses. As healthcare increasingly pivots towards personalized medicine, the identification of novel biomarkers through metabolomics advancements is becoming essential for in-vitro diagnostics, environmental toxicology assessment, and drug discovery processes. Over the past decade, the "omics" revolution has not only enhanced the technical capabilities of metabolomics but also broadened its relevance across various biomedical domains. This growth trajectory is expected to continue, fueled by the rising demand for precision medicine and integrative approaches to health diagnostics, propelling the Metabolomics market into new horizons of innovation and application.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Metabolomics Market Size by Product & Service & CAGR (2025-2032)

Market Overview
Metabolomics Instruments
Separation Tools
- Gas Chromatography
- High-performance Liquid Chromatography
- Ultra-performance Liquid Chromatography
- Capillary Electrophoresis
Detection Tools
- Nuclear Magnetic Resonance (NMR) Spectroscopy
- Mass Spectrometry (MS)
- Surface-Based Mass Analysis

Global Metabolomics Market Size by Bioinformatics Tools and Services & CAGR (2025-2032)

Market Overview
Bioinformatics Services
Bioinformatics Tools and Databases

Global Metabolomics Market Size by Application & CAGR (2025-2032)

Market Overview
Biomarker discovery
Drug discovery
Toxicology testing
Nutrigenomics
Functional Genomics
Personalized medicine
Other Applications

Global Metabolomics Market Size by Indication & CAGR (2025-2032)

Market Overview
Cancer
Cardiovascular Disorders
Neurological Disorders
Metabolic Disorders
Inborn Errors of Metabolism
Other Indications

Global Metabolomics Market Size by End User & CAGR (2025-2032)

Market Overview
Academic and Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Other End Users

Global Metabolomics Market Size by Company Type & CAGR (2025-2032)

Market Overview
Tier 1 Pharmaceutical Companies
Tier 2 Pharmaceutical Companies
Tier 3 Pharmaceutical Companies

Global Metabolomics Market Size & CAGR (2025-2032)

North America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- US
- Canada
Europe (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Waters Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bruker Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shimadzu Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (SCIEX) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Metabolon, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LECO Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Human Metabolome Technologies, Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GL Sciences, Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioocrates Life Sciences AG (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BASF SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MS-OMICS (Various locations)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Afekta Technologies Ltd. (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DNA Xperts Private Limited. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Metabolomic Technologies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kore Technology Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments